Recursion Pharmaceuticals (RXRX) EBT (2020 - 2026)
Recursion Pharmaceuticals (RXRX) posted EBT of -$122.1 million for Q1 2026, down 12.96% on a QoQ basis from -$108.1 million in Q4 2025, and up 39.74% year-over-year from -$87.4 million in Q1 2025.
Recursion Pharmaceuticals (RXRX) EBT (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals' EBT history runs 7 years deep, the most recent figure standing at -$122.1 million for Q1 2026.
- Quarterly EBT rose 39.74% year-over-year to -$122.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$564.4 million (up 1.9% YoY) and the FY2025 annual result came in at -$644.9 million, down 38.75% from the prior year.
- EBT was -$122.1 million for Q1 2026 at Recursion Pharmaceuticals, down from -$108.1 million in the prior quarter.
- Across five years, EBT topped out at -$56.0 million in Q1 2022 and bottomed at -$202.6 million in Q1 2025.
- A 5-year average of -$106.7 million and a median of -$95.7 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2025 — EBT slumped 119.9% — and 2026, when it soared 39.74%.
- Recursion Pharmaceuticals' EBT stood at -$64.5 million in 2022, then tumbled by 50.38% to -$97.1 million in 2023, then plunged by 84.32% to -$178.9 million in 2024, then jumped by 39.57% to -$108.1 million in 2025, then fell by 12.96% to -$122.1 million in 2026.
- Business Quant data shows RXRX's EBT at -$122.1 million in Q1 2026, -$108.1 million in Q4 2025, and -$162.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 438.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Recursion Pharmaceuticals | 1.57 Bn | 912.05 Mn | -6.02 Mn | -122.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -122.11 Mn |
| Dec 31, 2025 | -108.10 Mn |
| Sep 30, 2025 | -162.25 Mn |
| Jun 30, 2025 | -171.90 Mn |
| Mar 31, 2025 | -202.65 Mn |
| Dec 31, 2024 | -178.90 Mn |
| Sep 30, 2024 | -95.68 Mn |
| Jun 30, 2024 | -98.06 Mn |
| Mar 31, 2024 | -92.15 Mn |
| Dec 31, 2023 | -97.06 Mn |
| Sep 30, 2023 | -93.02 Mn |
| Jun 30, 2023 | -76.73 Mn |
| Mar 31, 2023 | -65.33 Mn |
| Dec 31, 2022 | -64.54 Mn |
| Sep 30, 2022 | -62.59 Mn |
| Jun 30, 2022 | -66.21 Mn |
| Mar 31, 2022 | -56.00 Mn |
| Dec 31, 2021 | -64.98 Mn |
| Sep 30, 2021 | -46.62 Mn |
| Jun 30, 2021 | -43.43 Mn |